{
    "clinical_study": {
        "@rank": "161378", 
        "arm_group": [
            {
                "arm_group_label": "B", 
                "arm_group_type": "No Intervention", 
                "description": "After accepting concurrent radiotherapy and chemotherapy, patients will just regularly follow up."
            }, 
            {
                "arm_group_label": "A", 
                "arm_group_type": "Experimental", 
                "description": "After accepting concurrent radiotherapy and chemotherapy, patients will receive 3 cycles of Dendritic and Cytokine-induced Killer Cells (DC-CIK)treatment."
            }
        ], 
        "brief_summary": {
            "textblock": "Concurrent of radiotherapy and chemotherapy is the main treatment method for patients with\n      nasopharyngeal carcinoma (NPC). However, Relapse remains the major cause of treatment\n      failure. A series of studies reported that dendritic and cytokine-induced killer cells\n      (DC-CIK) have a broad anti-tumor spectrum. We suppose that DC-CIK will improve the prognosis\n      of NPC. In this study, the patients with NPC will be treated with DC-CIK cells after\n      concurrent of chemotherapy and radiotherapy. The purpose of this study is to evaluate the\n      efficacy of DC-CIK for NPC."
        }, 
        "brief_title": "Study of DC-CIK to Treat NPC", 
        "completion_date": {
            "#text": "May 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Nasopharyngeal Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Nasopharyngeal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "About 60 patients with staging \u2161-\u2162 of NPC, after accepting concurrent radiotherapy and\n      chemotherapy, will be randomly divided into group A (receive DC-CIK treatment) or group B\n      (just regularly follow up), and the randomize ratio will be 1:1. Patients in group A will\n      receive 2-3 cycles of DC-CIK cells treatment (every 4 weeks). Patients in group B will have\n      no anti-tumor therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients with staging \u2161-\u2162 of NPC;\n\n          2. Patients who had completed concurrent of radiotherapy and chemotherapy;\n\n          3. Patients who have a life expectancy of at least 12 weeks;\n\n          4. Eastern Cooperative Oncology Group (ECOG) performance status was 0-1;\n\n          5. The bone marrow functioned normally (WBC > 4.0\u00d7109/L, Hb > 120 g/L, PLT > 100\u00d7109/L);\n\n          6. The ECG results were normal, and the liver and kidney were functional.\n\n        Exclusion Criteria:\n\n          1. Patients who had distant metastases by imaging studies;\n\n          2. Patients with uncontrolled infection; underlying disease that was severe or\n             life-threatening;\n\n          3. Patients who were pregnant or lactating;\n\n          4. ECOG perform status \u2265 2;\n\n          5. Patients who are suffering from auto immune diseases or patients who need to accept\n             glucocorticoid treatment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01821495", 
            "org_study_id": "NPC-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "A", 
                "intervention_name": "DC-CIK", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "A", 
                "description": "Concurrent of radiotherapy and chemotherapy plus 3 cycles of Dendritic and Cytokine-induced Killer Cells(DC-CIK) treatment", 
                "intervention_name": "Dendritic and Cytokine-induced Killer Cells", 
                "intervention_type": "Biological", 
                "other_name": "DC-CIK"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "NPC,DC-CIK", 
        "lastchanged_date": "April 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nanning", 
                    "country": "China", 
                    "state": "Guangxi", 
                    "zip": "530000"
                }, 
                "name": "Guangxi Medical University"
            }, 
            "investigator": {
                "last_name": "Hanfeng Liu, Master", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Controlled Study of Dendritic and Cytokine-induced Killer Cells (DC-CIK) Treatment in Patients With Staging \u2161-\u2162 of Nasopharyngeal Carcinoma", 
        "other_outcome": {
            "measure": "Laboratory findings", 
            "safety_issue": "No", 
            "time_frame": "1 month"
        }, 
        "overall_contact": {
            "email": "swl20012002@sohu.com", 
            "last_name": "Weiliang Sun, M.D.", 
            "phone": "86-771-3277289"
        }, 
        "overall_official": {
            "affiliation": "Guangxi Medical University", 
            "last_name": "Hanfeng Liu", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "progression-free survival(PFS)", 
            "safety_issue": "No", 
            "time_frame": "1 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01821495"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Guangxi Medical University", 
            "investigator_full_name": "Weiliang Sun", 
            "investigator_title": "investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "overall survival(OS)", 
            "safety_issue": "No", 
            "time_frame": "1 month"
        }, 
        "source": "Guangxi Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Guangxi Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}